Sign in with your email address username.


[Comment] Not another steroid trial: early low-dose hydrocortisone in preterm infants

In The Lancet, Baud and colleagues1 address a very important (and recurrent) topic in neonatology—the use of steroids to reduce the incidence of bronchopulmonary dysplasia in very preterm infants. This large multicentre double-blind randomised controlled trial shows that a large proportion of infants born at 24–27 weeks of gestation who were randomly assigned to receive low dose hydrocortisone (153 [60%] of 255) during their first 10 postnatal days survived to 36 weeks post conceptual age without bronchopulmonary dysplasia, compared with infants who received placebo (136 [51%] of 266).